La prescription et délivrance de médicaments hors AMM
toutes les informations utiles aux professionnels amenés à prescrire ou dispenser des médicaments hors autorisation de mise sur le marché (hors AMM).
Les prescriptions hors AMM
PRESCRIPTION HORS AMM JUSTIFIEE. = Conforme aux Données Acquises de la Science. AMM non mise à jour alors qu'il existe des données.
Les Prescriptions médicamenteuses hors AMM (Auto- risation de
21-Nov-2018 2) Le prescripteur qui prescrit une spécialité en dehors de son AMM doit faire figurer sur l'ordonnance la mention « prescription hors AMM » ce ...
Thesaurus for off-label indications for systemic antifungal agents
des indications hors-AMM des antifongiques systémiques a été élaboré afin de réactualiser les pratiques cliniques et de maîtriser la prescription hors AMM.
Prescriptions hors AMM en néonatologie
95%: 4.7 - 5.7) sans AMM. Parmi les 910 patients inclus 863 (94.8%) ont reçu au moins une prescription hors AMM dont 100% enfants moins de 31 semaine d'âge
Thesaurus for off-label indications for systemic antifungal agents
des indications hors-AMM des antifongiques systémiques a été élaboré afin de réactualiser les pratiques cliniques et de maîtriser la prescription hors AMM.
Groupe de travail n° 3 «Encadrer les prescriptions hors AMM»
12-Apr-2011 Le président a ouvert la séance consacrée aux remontées de données sur la prescription hors. AMM et aux systèmes d'information
Assises du médicament- Groupe 3
09-Mar-2011 La prescription hors AMM: état des lieux de ... Dans les limites fixées par la loi le médecin est libre de ses prescriptions qui seront.
Rapport Hors AMM pour ANM vs 26 11 18
Les Prescriptions médicamenteuses hors AMM (Autorisation de Mise sur le. Marché) en France. Une clarification est indispensable.
Dans la tourmente du Médiator®
L'article mentionne que la prescription hors AMM a été «< trouvée dans tous les pays où elle a été étudiée et dans toutes les structures: chirurgie.
La prescription et délivrance de médicaments hors AMM
La prescription hors AMM est prévue par le code de la santé publique (article L 5121-12-1 CSP) Elle doit demeurer exceptionnelle PHARMACIENS La dispensation hors AMM est légale et reste sous la responsabilité du pharmacien Conseil national de l'Ordre des médecins - Conseil national de l'Ordre des pharmaciens - septembre 2020
Searches related to les prescriptions hors amm
On entend par prescriptions hors AMM les prescriptions non conformes à l’AMM qui peuvent concerner notamment l’indication les caractéristiques des patients la voie d’administration les modalités d’administration la posologie la durée du traitement L’autorisation de mise sur le marché (AMM) est un acte administratif qui permet
![Thesaurus for off-label indications for systemic antifungal agents Thesaurus for off-label indications for systemic antifungal agents](https://pdfprof.com/Listes/21/8263-21document.pdf.jpg)
AL Bienvenu
1,2,9*, M Aussedat1, F Maldonado3, R Kavafian3, C Barbieri1, M Tod1,9, C Paillet3,4, L
Juillard
3,5,6, C Chidiac7,8,9, G Leboucher1,9
1 Service Pharmacie, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon2UMR-CNRS 5246, Campus Lyon La Doua, Université de Lyon, Lyon
3 Commission du Médicament et des Dispositifs Médicaux Stériles, Hospices Civils de Lyon, Lyon 4Service Pharmacie, Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon5Service de Néphrologie, Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon 6Univ Lyon1, Université de Lyon, Lyon
7Service des Mal adies In fectieuses et Trop icales, Groupement Hospitalier N ord, Hospices
Civils de Lyon, Lyon
8Université Claude Bernard Lyon 1, UFR Lyon Sud Charles Mérieux, Université de Lyon, Lyon
9Comité des Anti-Infectieux, Hospices Civils de Lyon, Lyon
*Corresponding author: A nne-Lise Bienvenu, 103 Grande Rue de la Croix-R ousse, 69004 Lyon. Email address: anne-lise.bienvenu@chu-lyon.fr (AL. Bienvenu) Mots clés : antifongiques, bon usage des antifongiquesKeywords: antifungals, antifungal stewardship
T T T TThésahu
u CandiaTbleu T1T.WTolrrd ooeinTg oTLdiuipi. oTsmhdWr luetl oTs cridWed oBTlnTumhoWldloT g oTengepWueinoTmidoIfzzTg oTWnuevinRetl oTo"ouhcetl oTWThuhTh.WPidhTWvenTg TdhWpulW.eo dT . oTrdWuetl oTp.enetl oT uTg TcWyudeo dT.WTrd opderueinTmidoTfzzaT dddaTx oTg dne-d oTd piccWngWueinoTg oToipehuhoToWkWnu oBTWenoeTtl T.WT PeP.eiRdWrme ToldTp Tol, uBTinuThuhTWnW."oh oaTw uu TdhgWpueinTo( ouTvWeu TgWnoT. TpWgd Tg(ln TWpueinTg TPinTloWR Tg oTWnuevinRetl oaT
aT x oT .eP ..hoT midoIfzzBT . oT WnuevinRetl oT pinp dnhoT uT . oT dhvhd np oT rWdT engepWueinT >rdirm".W0e BT rdh cruevBT credetl BT pldWuev)T inuT huhT kW.eghoT rWdT . T "dilr T fnuevinRetl oToiloT.(hReg Tg T.WTwicceooeinTglTzhgepWc nuT uTg oT*eorioeuevoTzhgepWl0T buhde. oT uT. TwiceuhTg oTfnueIQnv pue l0aT iaT xWT picr. 0evepWueinT g T .WT rdeo T nT pmWdR T g oT env pueinoT vinRetl oT enkWoek oT nhp ooeu Ttl Tp TumhoWldloToieuTrWduWRhT uTlue.eohTpicc TlnTilue.Tg(Weg T1T.WTrdeo T nTpmWdR T g oToeulWueinoTmidoTfzzaT Tu T T T T r éoAMdou u CandidaT :i..i2enRT um T d cikW.T ivT u cridWd"T ud Wuc nuT rdiuipi.T rdip gld oBT 2 T g k .ir gTWT um oWldloT vidT ivvI.WP .T engepWueinoT vidTo"ou cepTWnuevlnRW.oTWuT ildT vWpe.eu"TuiT lrgWu Tp.enepW.TrdWpuep oTWngTuiTpinudi.TivvI.WP .Trd opderueinoaT d dw.enepW.TrdWpuep TRleg .en oTWngT.eu dWuld TgWuWT2 d TWnW."E gaTsmeoT2id'T2WoTrWduTivTWnTWnuevlnRW.Tou 2WdgomerTrdiRdWcaT
d3vvI.WP .T2idgenRT>rdirm".W0eoBTrd cruek BT credepW.BTpldWuek )TWngTpidd oringenRT WnuevlnRW.oT WngT d v d np oT 2 d T kW.egWu gT P"T um T cl.uegeoper.enWd"T RdilrT vidT WnuevlnRW.T WR nuoTlng dTum TW ReoTivTum TwicceooeinTvidTum Tlo TivTgdlRoTWngTou de. Tc gepW.Tg kep oTWngTivTum TWnueIenv puek Tpicceuu aT
iwinoeg denRT um T picr. 0eu"T ivT enkWoek T vlnRW.T env pueinT cWnWR c nuBT umeoT um oWldloTn goTuiTP TomWd gTWngTlo gTWoTWTm .renRTuii.TuiTd ke 2TivvI.WP .ToeulWueinoaT T u T T T T2 Tg k .ir gTWT.ipW.Tum oWldloTvidTivvI.WP .TengepWueinoTvidTo"ou cepTWnuevlnRW.TWR nuoTWuTWT
uec T2m nTkWdeiloTd vidcoT2 d TP enRTrWoo gTinTum TvlngenRTivTm W.umTvWpe.eue oT34B56TWngT2m nTu cridWd"Tud Wuc nuTrdiuipi.Trdip gld oTouirr gTP enRTlo gaTT
sm TWpuekeu"IPWo gTrdepenRTo"ou cT2WoTecr. c nu gTenT:dWnp TenT5778TW.inRoeg TWTor pevepT vlngenRT r.WnT vidT 0r noek T gdlRoT WngT c gepW.T g kep oT WoT um T WcilnuT d .Wu gT uiT um T geWRnioeoId .Wu gTRdilrTgi oTniuTenp.lg Tum TvlngenRTivTolpmTrdiglpuoT346aT9 W.umTvWpe.eue oT cW"T pmWdR T 0r noek T gdlRoBT enp.lgenRT WT v 2T WnuevlnRW.T WR nuoBT enT WggeueinT uiT um T v oT d .Wu gT uiT um T geWRnioeoId .Wu gT RdilraT smeoT o"ou cT nold oT um T vWedT cWnWR c nuT ivT W..T rWue nuoTmioreuW.eE gTenT:dWnp aT winoeg denRTum TmeRmTpiouTivTum o TrdiglpuoBTWTumd IrWdu"TWRd c nuTvidTum Trdir dTlo TivT gdlRoT >:d npmT Wpdin"cT w:;)T 2WoT pinp.lg gT enT 5772mepmTum TvWpe.eu"TeoTWvve.eWu gT3>6aT3ldTvWpe.eu"Tum d vid TWRd gTuiTpicr."T2eumTum Tu dcoTivT
um Tw:;TvidTW..TWggeueinW.."Td ecPldo gTrdiglpuoaTwdeu deWTvidTum Trdir dTlo TivTgdlRoT2 d T g ven gTP"Tum T:d npmTfR np"TvidTum TbWv u"TivT9 W.umTLdiglpuoT>:d npmTWpdin"cTf?bz)TWoT rWduTivTRleg .en oTinTgdlRTou 2WdgomerTrlP.eom gTinTeuoT2 Poeu aT= ecPldo c nuTum d vid T Wrr.e gTuiTWn"TengepWueinTenp.lg gTenTum TcWd' uenRTWlumideEWueinTivTum TgdlRTWoT2 ..TWoTuiT engepWueinoT WooipeWu gT 2eumT WT u cridWd"T ud Wuc nuT rdiuipi.T rdip gld T Wrrdik gT P"T um T f?bzaTsm Tf?bzTW.oiTg ven gTlnWpp ruWP. ToeulWueinoT2m d TniTWggeueinW.Td ecPldo c nuT eoT riooeP. T WngT oeulWueinoT d tledenRT Woo ooc nuT vidT 2mepmT d ecPldo c nuT eoT riooeP. T rdikeg gTPiumTivTum Tvi..i2enRTpingeueinoTWd Tc u@Tum Trd opdeP dTomil.gT,louev"Tum Tlo TivT um T gdlRT loenRT .eu dWuld T d v d np oT WngT um T ,louevepWueinT omil.gT P T giplc nu gT enT um T rWue nu(oTd pidgaT QnT5745T rdip gld oT pW.. gT Au cridWd"T d picc ngWueinoT vidTlo BT >:d npmT Wpdin"cT =s;)T2 d Tecr. c nu gTuiTd r.Wp Tu cridWd"Tud Wuc nuTrdiuipi.Trdip gld oT386aT"leg .en oTvidT
um Trdir dTlo TivTgdlRoTWooipeWu gT2eumTu cridWd"Tud Wuc nuTrdiuipi.Trdip gld oTumloTniT .inR dTWrr.e gaTbenp T574CTum Td ecPldo c nuTivTWggeueinW.."TpmWdR gTgdlRoTeoTRdWnu gTP"T engepWueinTWngTniT.inR dTP"TgdlRaTQngepWueinoTpicr."enRT2eumTum TcWd' uenRTWlumideEWueinT WngTd ecPldoWP. T=s;Toue..TWrr."TuigW"aT9i2 k dBTniT=s;TvidTWnuevlnRW.TWR nuoTmWoToiTvWdT P nTRdWnu gaT3vvI.WP .Tlo TPWo gTinTdWueinW.Tp.enepW.TWdRlc nuoTWngT.eu dWuld Td v d np oT cW"T P Td ecPldo gT inT WTpWo IP"IpWo T PWoeoaT sm TwinudWpuT vidT ecrdikenRT um TtlW.eu"TWngT T T T T vvepe np"TivTpWd T>:d npmTWpdin"cTwfDEb)TeoTd r.WpenRTum Tw:;Toenp T574FBTPluTd tled c nuoT vidTum Trdir dTlo TivTgdlRoTd cWenTlnpmWnR gT3<6aT2 Tg peg gTuiTg k .irTWTum oWldloTvidTivvI.WP .TengepWueinoTvidTo"ou cepTWnuevlnRW.TWR nuoTuiT
picr noWu TvidTum Td cikW.TivTu cridWd"Tud Wuc nuTrdiuipi.Trdip gld oTWngTuiTpinudi.T oeulWueinoTd tledenRTivvI.WP .Trd opderueinoaT3vvI.WP .Trd opderueinoTWppilnuTvidT4GHTuiT87HTivT rd opderueinoT enT ildT vWpe.eu"BT g r ngenRT inT um T 2WdgoaT fT 5748T Woo ooc nuT ivT WnuevlnRW.T rd opderueinoTeg nueve gT 4FHT ivT ninIpicr.eWnuT rd opderueinoTvidT Wor dRe..ioeoTWngT 44HT vidT pWngegeWoeoaTsm o TninIpicr.eWnuTrd opderueinoT2 d TcWen."Tgl TuiTum T.Wp'TivTrd opdePenRT Rleg .en oTenTum TvWpe.eu"T>lnrlP.eom gTgWuW)aTsm Tg k .irc nuTivTum Tum oWldloT2WoTrWduTivTWT clpmT.WdR dToudWu R"TvidTWnuevlnRW.Tou 2WdgomerTWecenRTWuTdWueinW.eEenRTum Trd opderueinTivTWnuevlnRW.TWR nuoaT
sm Tum oWldloTWecoTuiTvl.ve..Tum Tn gTvidTWnTlrgWu TivTp.enepW.TrdWpuep oTPWo gTinTd p nuT0r duTd picc ngWueinoBTPluTW.oiTum Tn gTvidTpinoeg dWueinTivTivvI.WP .Trd opderueinoTivT
WnuevlnRW.TWR nuoaTfTcid TR.iPW.TiP, puek TeoTuiT nold Tum TvWedTcWnWR c nuTivTW..TrWue nuoTWoT Wpp ruWP. TivvI.WP .Trd opderueinoTWd TkW.egWu gTPWo gTinTWTpino noloaT2 T g k .ir gT um T um oWldloT vi..i2enRT WT p.io T WnW."oeoT ivT fc depWnT >Qnv pueiloT *eo Wo oT
bipe u"TivTfc depW)TWngTEldir WnTRleg .en oT>Eldir WnTbipe u"TivTw.enepW.TzepdiPei.iR"TWngT Qnv pueiloT*eo Wo o)TuiTpi.. puTtlW.eu"T keg np T. k .oTvidTum TkWdeiloTp.enepW.ToeulWueinoaT2m nT d picc ngWueinoT 2 d T .Wp'enRBT 2 T .ii' gT vidT ium dT or pevepT ope nuevepT Wduep. oT loenRT um T LlPz gIT gWuWPWo aT 3vvI.WP .T rd opderueinoT 2 d T W.oiT eng 0 gT PWo gT inT um T rdior puek T cineuidenRTivTivvI.WP .TengepWueinoTr dvidc gTP"Tum TrmWdcWpe oTWoTrWduTivTum Tw:;aT2 TW.oiT r dvidc gTWTpicrWdWuek TWnW."oeoTivTum TcWd' uenRTWlumideEWueinoTivTWnuevlnRW.TWR nuoT.eou gT enTildTvWpe.eu"TuiTeg nuev"Tium dTivvI.WP .ToeulWueinoTumWuT2il.gTmWk Tium d2eo TP Tceoo gTenT p.enepW.T rdWpuep aT sm T 2idgenRT ivT um T ivvI.WP .T oeulWueinoT 2WoT g peg gT PWo gT inT d p nuT .eu dWuld Td v d np oBTcWen."T 0r duTd picc ngWueinoBToiTWoTuiTP TPWo gTinTin TidTo k dW.T .eu dWuld T d v d np oaT sm T um oWldloT 2WoT um nT olPceuu gT uiT WngT kW.egWu gT P"T um T cl.uegeoper.enWd"TRdilrTvidTWnuevlnRW.TWR nuoTlng dTum TW ReoTivTum TwicceooeinTvidTum Tlo T ivTgdlRoTWngTou de. Tc gepW.Tg kep oTWngTivTum TfnueIenv puek Tpicceuu aT sWP. oT4TuiT>Tg uWe.Tum TivvI.WP .T2idgenRBTum TWnuevlnRW.TWR nuoTpinp dn gBTum Triu nueW.T tlW.eu"T keg np T . k .oT g ven gT P"T um T Qnv pueiloT *eo Wo oT bipe u"T ivT fc depWBT WngT um T .eu dWuld Td v d np oTP"TengepWueinT>rdirm".W0eoBTrd cruek BT credepW.BTpldWuek )aT T T T T u entdiséfntu fnuevlnRW.T rd opderueinT mWoT P pic T cid T picr. 0T ik dT um T rWouT " Wdo@T c"pi.iRepW.T geWRniouepT c umigoT Wd T cid T gek do BT um T nlcP dT ivTWkWe.WP. T WnuevlnRW.T WR nuoT mWoT enpd Wo gBTvlnRW.Tgeo Wo oTpWlo gTP"TdWd TidTd oeouWnuTvlnReTWd Tcid Tvd tl nu."TiPo dk gBT WngTrWue nuoTd tledenRTud Wuc nuTWd TciouTivu nTW.d Wg"TuW'enRTo k dW.Tud Wuc nuoTWngTWd T meRm."T ecclnig vepe nuaT sii.oTvidTWooeouenRTWnuevlnRW.Trd opderueinTWd T um d vid T n g gaT smeoTum oWldloTumloTvl.ve..oTumeoTn gTWoTum TciouTvd tl nuTivvI.WP .ToeulWueinoTWd T.eou gTenTum T um oWldloaT sm o T .ipW.T Rleg .en oT pil.gT o dk T WoT um T ilu.en T vidT g k .irenRT nWueinW.TRleg .en oT kW.egWu gT P"T ope nuevepT oipe ue oaT sm T um oWldloT eoT cWen."T Wec gT WuT rd opdePenRT
rm"oepeWnoBTciouTivu nTenv pueiloTgeo Wo Tor peW.eouoT2miTWd Tvd tl nu."Tpinvdinu gT2eumTivvI .WP .Trd opderueinoaTsm edTWpp ooTuiT.eu dWuld Td v d np oTd tled gTuiT,louev"Tum Trd opderueinTenT um TrWue nu(oTd pidgTeoTum d vid TvWpe.euWu gBT or peW.."TWoTum T,louevepWueinTeoTcWngWuid"TvidT ivvI.WP .T rd opderueinoT uiT iPuWenT d ecPldo c nuaT sm T um oWldloT eoT W.oiT Wec gT WuT mioreuW.T rmWdcWpeouoToiTumWuTum "TpWnTmWk TWTuii.TuiTkW.egWu TivvI.WP .Trd opderueinoaTsm Tum oWldloT umloTWpuoTWoTWTRlegenRTgiplc nuTivv denRTWnTmiciR n iloTdWn'enRTivTivvI.WP .TengepWueinoTenT mioreuW.T rmWdcWpe oT WngT riu nueW.."T nWP.enRT um T eg nuevepWueinT ivT ninIpicr.eWnuT p.enepW.T oeulWueinoaT f..TvWpe.eue oTpinvdinu gT2eumTivvI.WP .Trd opderueinoTpWnTlo TumeoTum oWldloTP"TWggenRTum edT or pevepTpmWdWpu deouepoTvidTWnuevlnRW.Trd opderueinoaTsm Tum oWldloTeoTWTrd opdePenRTuii.TumWuT n goT uiT P T pinuenlilo."T lrgWu gaT QuT 2e..T P T WgWru gT PWo gT inT um T d v d npenRT ivT n 2T WnuevlnRW.TWR nuoBTum TrlP.epWueinTivTn 2Tope nuevepTWduep. oBTWngTum Teg nuevepWueinTivTn 2TivvI .WP .Tp.enepW.ToeulWueinoaTsm TWnuevlnRW.Tou 2WdgomerTecr. c nu gTenTildTvWpe.eu"TpinudePlu gT uiT um T g k .irc nuTWngT geoo cenWueinTivTum T um oWldloTWngT nold oT euoT d Rl.WdT lrgWu aT T T T T rdgtnqipylaptou2 T2il.gT.e' TuiTumWn'Tum TfnuevlnRW.T"dilrBTum TwicceooeinTvidTum Tlo TivTgdlRoTWngT
ou de. Tc gepW.Tg kep oBTWngTum TfnueIenv puek Tpicceuu TivTum T9ioreuW.TivTx"inT>9iorep oT weke.oTg Tx"in)TvidTpinudePluenRTuiTum TkW.egWueinTivTum Tum oWldloBTWoT2 ..TWoTum TwinoiduelcT vidTWnueIrWdWoeuepTWngTWnuevlnRW.TWR nuoT>:d npmTWpdin"cTwWL:)aT T T entoAf sofntunxuMsoOnAéu f..TWlumidoTpinudePlu gTuiT2deuenRTum TWduep. TWngTg k .irenRTum Tum oWldloaT T -styftlu2 Tr dvidc gTumeoT2id'TWoTrWduTivTildTgWe."TWpuekeue oaT
u bpdiMAMofntunxuftopApéoéuu faIxaT:aT2WoTenkeu gTuiTpinv d np oTWoTor W' dTvidTzb*TWngTWoTWuu ng TvidTzb*TWngT"e. WgaT "aTxaT2WoTenkeu gTuiTpinv d np oTWoTWuu ng TWngJidTor W' dTvidTz".WnTWngTLveE daT zaTfaT2WoTenkeu gTuiTpinv d np oTWoTWuu ng TvidT"e. WgaT Tu T T T TTpxpAptdpéu
u346TxieTnKT577>I44LLTglT4FTghp cPd T577>Tg TvenWnp c nuTg T.WTohpldeuhToipeW. TrildT5778aT
fkWe.WP. Tvdic@T muuro@JJ222a. RevdWnp aRilkavdJWvvepms 0u agiMpegs 0u NO3=:sEPs77777758L5GCT>Wpp oo gT
frde.TT>Wpp oo gTfrde.T 3>6T*hpd uTnK577TglT58TWiSuT577 g oTrdigleuoT uTrd ouWueinoTc nueinnhT1T.QWduep. TxaT4C5I55IGTglTpig Tg T.WTohpldeuhToipeW. aT fkWe.WP. Tvdic@T muuro@JJ222a. RevdWnp aRilkavdJWvvepms 0u agiMpegs 0u NO3=:sEPs777777C>4454 T>Wpp oo gT
frde.T386T*hpd uTnKT5745IG85TglTLTcWeT5745Td .WuevTWl0Td piccWngWueinoTu cridWed oTgQlue.eoWueinT g oTorhpeW.euhoTrmWdcWp luetl oaTfkWe.WP. Tvdic@TT muuro@JJ222a. RevdWnp aRilkavdJ .eJg pd uJ5745J*J,iJu 0u T >Wpp oo gT frde.T
3<6T *hpd uT nKT 574GI gQWch.eidWueinTg T.WTtlW.euhT uTg T.Q vvepe np Tg oToienoT muuro@JJ222a. RevdWnp aRilkavdJ .eJg pd uJ574GJ8J57Jf:bb4G7>C4C*J,iJu 0u T >Wpp oo gT frde.TWording Liposomal
amphotericin B Inhaled
amphotericin B caspofungin fluconazole itraconazole micafungin posaconazole voriconazole References
"Prophylaxis for invasive fungal infections in at-risk patients, especially in patients presenting with prolonged neutropenia (>10 days)" Strong recommendation, high quality
evidence Sung AH, Marcella SW, Xie Y. An update to the cost- effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. J Med Econ 2015;18:341-8. Ebinger M, Schwarze CP, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis 2015;34:1189-200.
Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014;58:5758-65.
"Prophylaxis of invasive candidiasis in at-risk patients*, especially in intensive care units or in case of solid organ transplant" *Candida colonization, disease severity, exposure to broad- spectrum antibiotics, major and recent surgery especially at the abdominal level, necrotizing pancreatitis, dialysis, parenteral nutrition, corticosteroids, presence of a central venous catheter (Pappas PG, 2016) Weak recommendation, moderate
quality evidence / ESCMID BI Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18 Suppl 7:19-37. Quality evidence: BI Recommendations and quality evidence levels are from the Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA)
"Prophylaxis of invasive pulmonary aspergillosis in patients who underwent lung transplant or on a case-by-case basis in at-risk patients**, mainly in construction sites" **Refractory leukemia, solid tumors, solid organ transplants, corticosteroid treatment, COPD with progression of infiltrates despite antibiotic therapy, patients presenting with septic shock (Patterson TF, 2016) Strong recommendation, moderate quality
evidence Weak recommendation, low quality evidence
Strong recommendation, moderate quality
evidence Weak recommendation, low quality evidence
Strong recommendation, moderate quality
evidence Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63:e1-e60.
Koval C. Echinocandins for antifungal prophylaxis in liver transplant recipients: Advance in the field or variation on a theme? Liver Transpl. 2016; 22:396-8. Xing T, Zhong L, Peng Z. Safety and effectiveness of antifungal prophylaxis in preventing fungal infection after liver transplantation: a meta-analysis of randomized clinical trials. Int J Clin Pharmacol Ther 2016;54:564-71.
Chen YC, Huang TS, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC, Soong RS. Effect of Prophylactic Antifungal Protocols on the Prognosis of Liver Transplantation: A Propensity Score Matching and Multistate Model Approach. Biomed Res Int 2016; 2016:6212503. Tableau 2. Thésaurus hors AMM des antifongiques en préemptif et empirique Table 2. Off-label thesaurus for preemptive and empirical antifungal therapies Wording
Liposomal
amphotericin B Inhaled
amphotericin B caspofungin fluconazole itraconazole micafungin posaconazole voriconazole References
"Preemptive treatment of invasive fungal infections in asymptomatic or febrile at-risk patients, with positive biomarker, especially in patients presenting with prolonged neutropenia (>10 days) or in patients who underwent lung transplant" X X Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile
neutropenic patient: a prospective randomized study. Int J Infect Dis 2011;15:e350-6. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-51. Maertens J, Theunissen K, Verhoef G,
Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-
based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50.
Recommendations and quality evidence levels are from the Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA)
"Preemptive treatment of invasive candidiasis in asymptomatic or febrile at-risk patients*, with positive biomarker, especially in intensive care units
or in case of solid organ transplant" *Candida colonization, disease severity, exposure to broad-spectrum antibiotics, major and recent surgery especially at the abdominal level, necrotizing pancreatitis, dialysis, parenteral nutrition, corticosteroids, presence of a central venous catheter (Pappas PG, 2016) Strong recommendation,
moderate quality evidence Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50.
quotesdbs_dbs33.pdfusesText_39
[PDF] AUTO-DIAGNOSTIC DU MANAGER D après P. Hersey et K.Blanchard
[PDF] Utiliser un Tableau Blanc Interactif - Travaux Pratiques
[PDF] entreprendre à de nouvelles attentes?
[PDF] OBJET : Prescription visant les procédures de mise en application de l OCRCVM
[PDF] LA SECONDE PARTIE DE CARRIÈRE : COMPARAISON HOMMES/FEMMES
[PDF] Les conditions d une synergie entre certifications qualité :
[PDF] LES 5 PLUS GROSSES IDEES RECUES DES FEMMES ENCEINTES SUR LE TABAC
[PDF] Les nombres de 0 à lecture, écriture décomposition, comparaison, rangement. Les grands nombres : Lecture, écriture, décomposition
[PDF] Formation Dirigeant-e de PME
[PDF] COLLOQUE 14 11 2013 Encouragement à la juste prescription en médecine humaine: profils de prescription des médecins - la convention médicale
[PDF] Présenta)on du manuel numérique enrichi Premium
[PDF] Alcool, tabac et drogues illicites : Géographie des pratiques addictives en France
[PDF] Ministère de la Santé et Soins de longue durée Protocole d entreposage et de manipulation des vaccins, 2016
[PDF] Réunion préparatoire à l Assemblée générale de la CARMF. 16 septembre 2010
[PDF] MASTER MEEF - PLC - ITALIEN
3>6T*hpd uTnK577TglT58TWiSuT577 g oTrdigleuoT uTrd ouWueinoTc nueinnhT1T.QWduep. TxaT4C5I55IGTglTpig Tg T.WTohpldeuhToipeW. aT fkWe.WP. Tvdic@T muuro@JJ222a. RevdWnp aRilkavdJWvvepms 0u agiMpegs 0u NO3=:sEPs777777C>4454 T>Wpp oo gT
frde.T386T*hpd uTnKT5745IG85TglTLTcWeT5745Td .WuevTWl0Td piccWngWueinoTu cridWed oTgQlue.eoWueinT g oTorhpeW.euhoTrmWdcWp luetl oaTfkWe.WP. Tvdic@TT muuro@JJ222a. RevdWnp aRilkavdJ .eJg pd uJ5745J*J,iJu 0u T >Wpp oo gT frde.T
3<6T *hpd uT nKT 574GI gQWch.eidWueinTg T.WTtlW.euhT uTg T.Q vvepe np Tg oToienoT muuro@JJ222a. RevdWnp aRilkavdJ .eJg pd uJ574GJ8J57Jf:bb4G7>C4C*J,iJu 0u T >Wpp oo gT frde.TWording Liposomal
amphotericin B Inhaled
amphotericin B caspofungin fluconazole itraconazole micafungin posaconazole voriconazole References
"Prophylaxis for invasive fungal infections in at-risk patients, especially in patients presenting with prolonged neutropenia (>10 days)" Strong recommendation, high quality
evidence Sung AH, Marcella SW, Xie Y. An update to the cost- effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. J Med Econ 2015;18:341-8. Ebinger M, Schwarze CP, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis 2015;34:1189-200.
Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014;58:5758-65.
"Prophylaxis of invasive candidiasis in at-risk patients*, especially in intensive care units or in case of solid organ transplant" *Candida colonization, disease severity, exposure to broad- spectrum antibiotics, major and recent surgery especially at the abdominal level, necrotizing pancreatitis, dialysis, parenteral nutrition, corticosteroids, presence of a central venous catheter (Pappas PG, 2016) Weak recommendation, moderate
quality evidence / ESCMID BI Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18 Suppl 7:19-37. Quality evidence: BI Recommendations and quality evidence levels are from the Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA)
"Prophylaxis of invasive pulmonary aspergillosis in patients who underwent lung transplant or on a case-by-case basis in at-risk patients**, mainly in construction sites" **Refractory leukemia, solid tumors, solid organ transplants, corticosteroid treatment, COPD with progression of infiltrates despite antibiotic therapy, patients presenting with septic shock (Patterson TF, 2016) Strong recommendation, moderate quality
evidence Weak recommendation, low quality evidence
Strong recommendation, moderate quality
evidence Weak recommendation, low quality evidence
Strong recommendation, moderate quality
evidence Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63:e1-e60.
Koval C. Echinocandins for antifungal prophylaxis in liver transplant recipients: Advance in the field or variation on a theme? Liver Transpl. 2016; 22:396-8. Xing T, Zhong L, Peng Z. Safety and effectiveness of antifungal prophylaxis in preventing fungal infection after liver transplantation: a meta-analysis of randomized clinical trials. Int J Clin Pharmacol Ther 2016;54:564-71.
Chen YC, Huang TS, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC, Soong RS. Effect of Prophylactic Antifungal Protocols on the Prognosis of Liver Transplantation: A Propensity Score Matching and Multistate Model Approach. Biomed Res Int 2016; 2016:6212503. Tableau 2. Thésaurus hors AMM des antifongiques en préemptif et empirique Table 2. Off-label thesaurus for preemptive and empirical antifungal therapies Wording
Liposomal
amphotericin B Inhaled
amphotericin B caspofungin fluconazole itraconazole micafungin posaconazole voriconazole References
"Preemptive treatment of invasive fungal infections in asymptomatic or febrile at-risk patients, with positive biomarker, especially in patients presenting with prolonged neutropenia (>10 days) or in patients who underwent lung transplant" X X Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile
neutropenic patient: a prospective randomized study. Int J Infect Dis 2011;15:e350-6. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-51. Maertens J, Theunissen K, Verhoef G,
Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-
based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50.
Recommendations and quality evidence levels are from the Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA)
"Preemptive treatment of invasive candidiasis in asymptomatic or febrile at-risk patients*, with positive biomarker, especially in intensive care units
or in case of solid organ transplant" *Candida colonization, disease severity, exposure to broad-spectrum antibiotics, major and recent surgery especially at the abdominal level, necrotizing pancreatitis, dialysis, parenteral nutrition, corticosteroids, presence of a central venous catheter (Pappas PG, 2016) Strong recommendation,
moderate quality evidence Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50.
quotesdbs_dbs33.pdfusesText_39
[PDF] AUTO-DIAGNOSTIC DU MANAGER D après P. Hersey et K.Blanchard
[PDF] Utiliser un Tableau Blanc Interactif - Travaux Pratiques
[PDF] entreprendre à de nouvelles attentes?
[PDF] OBJET : Prescription visant les procédures de mise en application de l OCRCVM
[PDF] LA SECONDE PARTIE DE CARRIÈRE : COMPARAISON HOMMES/FEMMES
[PDF] Les conditions d une synergie entre certifications qualité :
[PDF] LES 5 PLUS GROSSES IDEES RECUES DES FEMMES ENCEINTES SUR LE TABAC
[PDF] Les nombres de 0 à lecture, écriture décomposition, comparaison, rangement. Les grands nombres : Lecture, écriture, décomposition
[PDF] Formation Dirigeant-e de PME
[PDF] COLLOQUE 14 11 2013 Encouragement à la juste prescription en médecine humaine: profils de prescription des médecins - la convention médicale
[PDF] Présenta)on du manuel numérique enrichi Premium
[PDF] Alcool, tabac et drogues illicites : Géographie des pratiques addictives en France
[PDF] Ministère de la Santé et Soins de longue durée Protocole d entreposage et de manipulation des vaccins, 2016
[PDF] Réunion préparatoire à l Assemblée générale de la CARMF. 16 septembre 2010
[PDF] MASTER MEEF - PLC - ITALIEN
T>Wpp oo gT
frde.TT >Wpp oo gT frde.T
Liposomal
amphotericin BInhaled
amphotericin B caspofungin fluconazole itraconazole micafungin posaconazole voriconazoleReferences
"Prophylaxis for invasive fungal infections in at-risk patients, especially in patients presenting with prolonged neutropenia (>10 days)"Strong recommendation, high quality
evidence Sung AH, Marcella SW, Xie Y. An update to the cost- effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. J Med Econ 2015;18:341-8. Ebinger M, Schwarze CP, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis2015;34:1189-200.
Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. AntimicrobAgents Chemother 2014;58:5758-65.
"Prophylaxis of invasive candidiasis in at-risk patients*, especially in intensive care units or in case of solid organ transplant" *Candida colonization, disease severity, exposure to broad- spectrum antibiotics, major and recent surgery especially at the abdominal level, necrotizing pancreatitis, dialysis, parenteral nutrition, corticosteroids, presence of a central venous catheter (Pappas PG, 2016)Weak recommendation, moderate
quality evidence / ESCMID BI Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18 Suppl 7:19-37. Quality evidence: BIRecommendations and quality evidence levels are from the Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA)
"Prophylaxis of invasive pulmonary aspergillosis in patients who underwent lung transplant or on a case-by-case basis in at-risk patients**, mainly in construction sites" **Refractory leukemia, solid tumors, solid organ transplants, corticosteroid treatment, COPD with progression of infiltrates despite antibiotic therapy, patients presenting with septic shock (Patterson TF, 2016)Strong recommendation, moderate quality
evidenceWeak recommendation, low quality evidence
Strong recommendation, moderate quality
evidenceWeak recommendation, low quality evidence
Strong recommendation, moderate quality
evidence Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis2016;63:e1-e60.
Koval C. Echinocandins for antifungal prophylaxis in liver transplant recipients: Advance in the field or variation on a theme? Liver Transpl. 2016; 22:396-8. Xing T, Zhong L, Peng Z. Safety and effectiveness of antifungal prophylaxis in preventing fungal infection after liver transplantation: a meta-analysis of randomized clinical trials.Int J Clin Pharmacol Ther 2016;54:564-71.
Chen YC, Huang TS, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC, Soong RS. Effect of Prophylactic Antifungal Protocols on the Prognosis of Liver Transplantation: A Propensity Score Matching and Multistate Model Approach. Biomed Res Int 2016; 2016:6212503. Tableau 2. Thésaurus hors AMM des antifongiques en préemptif et empirique Table 2. Off-label thesaurus for preemptive and empirical antifungal therapiesWording
Liposomal
amphotericin BInhaled
amphotericin B caspofungin fluconazole itraconazole micafungin posaconazole voriconazoleReferences
"Preemptive treatment of invasive fungal infections in asymptomatic or febrile at-risk patients, with positive biomarker, especially in patients presenting with prolonged neutropenia (>10 days) or in patients who underwent lung transplant" X XTan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile
neutropenic patient: a prospective randomized study. Int J Infect Dis 2011;15:e350-6. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-51.Maertens J, Theunissen K, Verhoef G,
Verschakelen J, Lagrou K, Verbeken E, et al.Galactomannan and computed tomography-
based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.Clin Infect Dis 2005;41:1242-50.
Recommendations and quality evidence levels are from the Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA)
"Preemptive treatment of invasive candidiasis in asymptomatic or febrile at-risk patients*, with positive biomarker, especially in intensive care units
or in case of solid organ transplant" *Candida colonization, disease severity, exposure to broad-spectrum antibiotics, major and recent surgery especially at the abdominal level, necrotizing pancreatitis, dialysis, parenteral nutrition, corticosteroids, presence of a central venous catheter (Pappas PG, 2016)Strong recommendation,
moderate quality evidencePappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50.
quotesdbs_dbs33.pdfusesText_39[PDF] Utiliser un Tableau Blanc Interactif - Travaux Pratiques
[PDF] entreprendre à de nouvelles attentes?
[PDF] OBJET : Prescription visant les procédures de mise en application de l OCRCVM
[PDF] LA SECONDE PARTIE DE CARRIÈRE : COMPARAISON HOMMES/FEMMES
[PDF] Les conditions d une synergie entre certifications qualité :
[PDF] LES 5 PLUS GROSSES IDEES RECUES DES FEMMES ENCEINTES SUR LE TABAC
[PDF] Les nombres de 0 à lecture, écriture décomposition, comparaison, rangement. Les grands nombres : Lecture, écriture, décomposition
[PDF] Formation Dirigeant-e de PME
[PDF] COLLOQUE 14 11 2013 Encouragement à la juste prescription en médecine humaine: profils de prescription des médecins - la convention médicale
[PDF] Présenta)on du manuel numérique enrichi Premium
[PDF] Alcool, tabac et drogues illicites : Géographie des pratiques addictives en France
[PDF] Ministère de la Santé et Soins de longue durée Protocole d entreposage et de manipulation des vaccins, 2016
[PDF] Réunion préparatoire à l Assemblée générale de la CARMF. 16 septembre 2010
[PDF] MASTER MEEF - PLC - ITALIEN